FSD Pharma VOTE GOLD Dr. Raza Bokhari and his collaborating directors have spent shareholder money in these attempts to entrench themselves and prevent shareholders from having a say in the leadership of the company:
Failure to Achieve Stated Goals: o h n the o ent e se e e
goals. To date, Dr. Bokhari and his collaborating directors have failed to achieve any of
these objectives: (i) while the Company’s Phase 2 clinical trial was approved in September 2020, to date the Company has announced the enrollment of only one patient, out of an "expecte " 352 p t ents w thout p o ng spec cs on n fu the en o ment ( ) h s been unable to dispose of the Cobourg Property, and (iii) has failed to identify any appropriate strategic acquisition opportunities, instead attempting (and failing) to
execute transactions in unrelated industries and without adequate diligence.
The Shareholder Meeting: The company has not held a shareholder meeting since 2019, yet Dr. Bokhari and his collaborating directors used company funds to delay holding a
meeting for as long as possible and have taken other actions to interfere with the democratic right of shareholders to determine who will serve as directors.
The Court Order: Dr. Raza Bokhari and his collaborating directors attempted to enter into a transaction that would have irreparably harmed the company, resulting in a court order
preventing them from undertaking the transaction or taking any other actions outside the ordinary course of business prior to the May 14, 2021 shareholder meeting (the “Meeting”).
Dilution: In just two months, Dr. Raza Bokhari and his collaborating directors have increased the number of outstanding Class B Shares by
a staggering 88% while the share price was close to its all-time lows. Issuing this large number of shares has further depressed the share price.
Share Grants: Dr. Raza Bokhari and his collaborating directors granted themselves excessive compensation for services not yet
rendered worth approximately $6.7 million, comprised of cash and/
or Class B Shares and such shares became subject to a court order prohibiting them from being voted at the Meeting.
Lack of Transparency: Repeated failures to disclose material information to shareholders, such as the court order and the resignation of the newly-
hired CEO of FSD BioSciences, Inc.
Expenses: The collaborating directors approved over US $1.4 millionof Dr. Raza Bokhari’s expenses in 2020, with little transparency or explanation